Literature DB >> 16899963

Distinguishing between hypochondriasis and somatization disorder: a review of the existing literature.

Russell Noyes1, Scott Stuart, David B Watson, Douglas R Langbehn.   

Abstract

A valid classification is important for further understanding of the somatoform disorders. The main disorders in this grouping - somatization disorder and hypochondriasis - have lengthy historical traditions and are defined in a contrasting manner. Various authors point to distinguishing demographic and clinical features, but there have been few direct comparisons of patients with these disorders. A review of the literature indicates those domains where differences are most likely to be found. Research assessing these may serve to refine and validate these key somatoform categories and/or dimensions.

Entities:  

Mesh:

Year:  2006        PMID: 16899963     DOI: 10.1159/000093948

Source DB:  PubMed          Journal:  Psychother Psychosom        ISSN: 0033-3190            Impact factor:   17.659


  5 in total

1.  The Association of Sensory Responsiveness with Somatic Symptoms and Illness Anxiety.

Authors:  Donja Rodic; Andrea Hans Meyer; Roselind Lieb; Gunther Meinlschmidt
Journal:  Int J Behav Med       Date:  2016-02

Review 2.  Advances in understanding illness anxiety.

Authors:  Kelli J Harding; Natalia Skritskaya; Emily Doherty; Brian A Fallon
Journal:  Curr Psychiatry Rep       Date:  2008-08       Impact factor: 5.285

3.  Somatization in Post-Concussion Syndrome: A Retrospective Study.

Authors:  Kenneth Perrine; James C Gibaldi
Journal:  Cureus       Date:  2016-08-19

4.  A-MUPS score to differentiate patients with somatic symptom disorder from those with medical disease for complaints of non-acute pain.

Authors:  Shingo Suzuki; Yoshiyuki Ohira; Kazutaka Noda; Masatomi Ikusaka
Journal:  J Pain Res       Date:  2017-06-07       Impact factor: 3.133

5.  Psychosomatic syndromes and anorexia nervosa.

Authors:  Giovanni Abbate-Daga; Nadia Delsedime; Barbara Nicotra; Cristina Giovannone; Enrica Marzola; Federico Amianto; Secondo Fassino
Journal:  BMC Psychiatry       Date:  2013-01-09       Impact factor: 3.630

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.